The research team consists of Dr. Doorish who operated his laboratory at Columbia University from 1996 - 1999. The other members of the research team are members of the Columbia Faculty. An expert in cellular physiology is Dr. Jan P. Koniarek. He has been at Columbia since 1984. From 1982-1984, Dr. Koniarek served as a patent examiner at the US Patent and Trademark Office. Dr. Koniarek received his doctorate in Biology in 1979 from New York University.

In the area of chemical engineering, is Dr. Carl C. Gryte who is a tenured professor and Vice-Chairman of Chemical Engineering, Columbia University. He has been at Columbia since 1971. Dr. Gryte received his doctorate in Polymer Chemistry in 1970 from the Polytechnic Institute of Brooklyn.

Joseph R.Flicek specializes in starting and establishing new businesses. Mr. Flicek created and established the New Ventures group of the Science & Technology Ventures Office at Columbia University in 1996. Under his leadership Columbia participated in the formation of over 40 new Columbia University portfolio companies through 2001, five of which are publicly traded. The Columbia portfolio companies have raised over $1 billion in venture and public market financings, and have generated more than 1,500 jobs. Mr. Flicek dynamically brought together faculty members, industry and venture capital groups to start new business ventures based on Columbia University intellectual property and research from the more than 7,000 faculty members and 2,500 laboratories. Columbia University is ranked number one among universities in licensing and generates over $150 million per year.

Mr. Flicek is President of Blake Technologies, Ltd. and is currently serving as Chief Executive Officer of Supertron Technologies, Inc., an MRI Medical Device company, with expertise in building high temperature superconducting circuits. The Company’s Investors asked Mr. Flicek to assist in repositioning Supertron as a value added asset in the MRI marketplace. Mr. Flicek was a preferred supplier to J&J through Quality First program when he ran the Hydrogel Medical Device Company in the early 90s.

Dr. Douglas Smith of the University of Pennsylvania Medical Center. Dr. Smith is currently Professor of Neurosurgery and Director of the Center for Brain Injury and Repair at the University of Pennsylvania. Over the last 12 years, he has devoted his full-time efforts to neurotrauma research following completion of fellowships in both molecular biology and neurotrauma at the University of Connecticut. His laboratory examines mechanisms of nerve fiber (axon) damage and repair in traumatic brain injury and spinal cord injury. Specific research interests include examining the effects of mechanical deformation of axons, tissue engineering approaches for nerve repair, neuroimaging, and the link between neurodegenerative diseases and traumatic brain injury. These efforts have resulted in over 100 published reports from his laboratory. Dr. Smith's very impressive and unique research may be complimentary to that of Doorish Ophthalmic Technologies.